文献速递消化道肿瘤与早癌肝病

抗生素使用与胃肠道及肝癌免疫检查点抑制剂治疗不良结局相关:一项荟萃分析

Antibiotic Use Linked to Worse Outcomes in Patients With Gastrointestinal and Liver Cancer on Immune Checkpoint Inhibitors: A Meta-Analysis.
PubMed 文献 · Am J Gastroenterol · 2026-02-12

结果显示抗生素使用与更差的总生存(HR 1.56)、无进展生存(HR 1.48)和疾病控制率(OR 0.55)相关,但客观缓解率无显著差异。亚组分析中肝细胞癌和上消化道癌结果一致,而结直肠癌研究显示总生存改善。

要点

  • 抗生素使用与ICI治疗胃肠道/肝癌患者更差的总生存和无进展生存相关。
  • 抗生素使用与更低的疾病控制率相关,但客观缓解率无显著差异。
  • 亚组分析结果因癌种而异,结直肠癌研究显示总生存改善。

核心结论

  • 抗生素使用与接受ICI治疗的胃肠道或肝癌患者更差的结局相关,应谨慎评估其合理性。

主要发现

  • 抗生素使用与更差的总生存相关(HR 1.56;95% CI:1.23-1.98;I2 = 87.3%)。
  • 抗生素使用与更差的无进展生存相关(HR 1.48;95% CI:1.15-1.90;I2 = 88.3%)。
  • 抗生素使用与更低的疾病控制率相关(OR 0.55;95% CI:0.33-0.90;I2 = 65.0%)。
  • 客观缓解率无显著差异(OR 1.01;95% CI:0.78-1.31;I2 = 0%)。
  • 肝细胞癌中抗生素使用与更差的总生存(HR 1.49;95% CI:1.24-1.79)和无进展生存(HR 1.25;95% CI:1.01-1.56)相关;上消化道癌中总生存(HR 2.40;95% CI:1.48-3.90)和无进展生存(HR 2.15;95% CI:1.18-3.91)更差;结直肠癌研究显示总生存改善(HR 0.58;95% CI:0.45-0.75)。

临床怎么用

  • 对接受ICI治疗的胃肠道或肝癌患者,应严格掌握抗生素使用指征并谨慎评估。

局限性

  • 需要前瞻性研究验证这些结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Immune checkpoint inhibitors (ICIs) are increasingly used in gastrointestinal and liver cancers. However, antibiotic-induced gut microbiota disruption may influence ICI effectiveness. The objective of this study was to evaluate association between antibiotic use and clinical outcomes among patients with gastrointestinal and liver cancers receiving ICI therapy. METHODS: In this meta-analysis, we searched studies involving adults with gastrointestinal or liver cancers treated with ICIs, comparing outcomes between patients with and without antibiotic use. Eligible studies reported hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) for overall survival (OS), progression-free survival (PFS), objective response rate, or disease control rate. Random-effects models were used for pooled analyses. RESULTS: Twenty-eight studies were included. Antibiotic use was associated with worse OS (HR 1.56; 95% CI: 1.23-1.98; I2 = 87.3%), PFS (HR 1.48; 95% CI: 1.15-1.90; I2 = 88.3%), and disease control rate (OR 0.55; 95% CI: 0.33-0.90; I2 = 65.0%), but no significant difference in objective response rate (OR 1.01; 95% CI: 0.78-1.31; I2 = 0%). Results were consistent in subgroup analyses by ICI type and timing of antibiotic administration. Antibiotic use was associated with worse OS and PFS in hepatocellular carcinoma (HR for OS: 1.49; 95% CI: 1.24-1.79; HR for PFS: 1.25; 95% CI: 1.01-1.56) and upper gastrointestinal cancers (HR for OS: 2.40; 95% CI: 1.48-3.90; HR for PFS: 2.15; 95% CI: 1.18-3.91), whereas colorectal cancer studies showed improved OS (HR: 0.58; 95% CI: 0.45-0.75). DISCUSSION: Antibiotic use is associated with worse outcomes in patients with gastrointestinal or liver cancer receiving ICIs and should be carefully justified. Prospective studies are needed to validate these results.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Rezaee-Zavareh MS, Karimi-Sari H, Parhizkar Roudsari P, et al. Antibiotic Use Linked to Worse Outcomes in Patients With Gastrointestinal and Liver Cancer on Immune Checkpoint Inhibitors: A Meta-Analysis. Am J Gastroenterol. 2026. PMID: 41677135. doi:10.14309/ajg.0000000000003956

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。